This product is used during procedures for bone tissue repair and regeneration on the area where bone damage has occurred. And it is formulated from the mixture of demineralized bone matrix (DBM, which obtained from the processing of human bones) and biodegradable carrier.
-This product is made from the mixture of DBM obtained from the bones of donated dead bodies and viscous carrier. DBM is known to form new bones for it contains bone morphogenetic proteins (BMP), and it can be applied to various affected parts of the patient and easy to use because it is injectable.
-Puttu like DBM in Syringe - reeduces bone loss&easy-to-use
-Moldable - filling various type of bone defects
-Carrier - high visco-elasticity
Cellumed Inc is a leading biotech company dedicated to developing bone graft substitution based on human tissue graft. Moreover, the company concentrates its R&D efforts on bio-similar business that develops human recombinant protein for treatment, employing genetic recombination technology. We are in pursuit of high value products with advanced biotechnology. Cellumed is the most prominent biotech company in Korea. Cellumed Biomaterial Medical-Engineering Laboratory (BMEL), affiliated with Cellumed Inc., was established in 2006. Since then, Cellumed has built the biggest GTP facility of Clean Room for tissue processing in Asia which is approved by KFDA and FDA for its safeness and effectiveness. Cellumed BMEL runs Korea’s 1st tissue bank with many highly educated tissue engineering specialists. Cellumed BMEL is also equipped with GMP facility for producing medical device and highly advanced facility for developing biomaterial, synthetic material, growth factor, and stem cell medicine. Cellumed BMEL holds strong workmanship with highly-educated researchers, who have passion for excellence in developing new product and handling and regulatory affairsThe efforts of those researchers led to Cellumed developing widely ranging high value products as well as succeeding in mass production of CHO-cell derived rhBMP2 for the first time in Asia. As a result, Cellumed has succeeded in extraction of mass volume of Cho-cell derived recombinant BMPs, and domestic production of complete artificial knee joint for the first time in Korea.